慢性淋巴细胞白血病合并真性红细胞增多症一例JAK2V617F突变研究
被引量:2
摘要
1病例报告
患者男,85岁。因“体柃发现血细胞增多2个月余”于2010-02—06入住杭州市第一人民医院血液科。
出处
《中华肿瘤防治杂志》
CAS
北大核心
2014年第3期232-233,236,共3页
Chinese Journal of Cancer Prevention and Treatment
参考文献16
-
1Campbell PJ,Green AR. The myeloproliferative disorders[J].{H}New England Journal of Medicine,2006,(23):2452-2466.
-
2Kikushige Y,Ishikawa F,Miyamoto T. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia[J].{H}CANCER CELLS,2011,(02):246-259.
-
3Weigert O,Weinstock DM. The evolving contribution of hematopoietic progenitor cells to lymphomagenesis[J].{H}Blood,2012,(13):2553-2561.
-
4Laurenti L,Tarnani M,Nichele I. The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms:a retrospective multicentric GINEMA experience[J].{H}American Journal of Hematology,2011,(12):1007-1012.
-
5Swierczek S,Nausova J,Jelinek J. Concomitant JAK2 V617Fpositive polycythemia vera and B-cell chronic lymphocytic leukemia in three patientsoriginating from two separate hematopoietic stem cells[J].{H}American Journal of Hematology,2013,(02):157-158.
-
6Zehentner BK,Loken MR,Wells DA. Jak2 mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders[J].{H}American Journal of Hematology,2006,(10):806-807.
-
7牛志云,郭晓玲,张敬宇,杨琳,罗建民.CMPN基因突变及其机制与生物学意义的探讨[J].中华肿瘤防治杂志,2013,20(15):1175-1178. 被引量:1
-
8James C,Ugo V,Le Couédic JP. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera[J].{H}NATURE,2005,(7037):1144-1148.
-
9Baxter EJ,Scott LM,Campbell PJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[J].{H}LANCET,2005,(9484):1054-1061.
-
10Henry L,Carillo S,Jourdan E. Association of essential thrombocythemia and chronic lymphocytic leukemia:absence of the V617F JAK2 mutation in the lymphoid compartment[J].{H}American Journal of Hematology,2007,(06):500-501.
二级参考文献13
-
1James C,Ugo V,Le Couedic JP,et al. A unique clonal JAK2 mu-tation leading to constitutive signalling causes polycythaemiavera[J]. Nature,2005 ,434(7037) : 1144-1148.
-
2Kannim S,Thongnoppakhun W, Auewarakul CU. Two-round al-lele specific-polymerase chain reaction:a simple and highly sensi-tive method for JAK2-V617F mutation detection[J]. Clin ChimActa,2009,401(1-2);148-151.
-
3Levine RL ? W alleigh M, Cools J ? et al. Activating mutation in thetyrosine kinase JAK2 in polycythmia vera,essential thrombo-cythmi-a,and myeloid metaplasia with myelofibrosis[J]. CancerCell,2005,7(4) :387-397.
-
4Laubach JP,Fu P, Jiang XH,et al. Polycythemia vera erythroidprecursors exhibit increased proliferation and apoptosis resist-ance associated with abnormal RAS and PI3K pathway activation[J]. Exp Hematol,2009,37(12) :1411-1422.
-
5Panani AD. Janus kinase 2 mutations in Phladelphia negative chronicmyeloproliferat ive disorders:climcal implications[J]. Cancer Letters,2009,284(1):7-14.
-
6Oku S, Takenaka K, Kuriyama T,et al. JAK2V617F uses distinctsignalling pathways to induce cell proliferation and neutrophil activa-tion[J]. Br J Haematol,2010,150(3) :334-344.
-
7Chen CC,Stairs DB,Boxer RB. Autocrine prolactin induced bythe Pten-Akt pathway is required for lactation initiation and pro-vides a direct link between the Akt and Stat5 pathways [J].Genes Dev,2012,26(19) :2154-2168.
-
8Tyler RK’Shpiro N,Marquez R,et al. VX-680 inhibits AuroraA and Aurora B kinase activity in human cells[J], Cell Cycle?2007,6(22):2846-2854.
-
9Muller P,Boutros M, Zeidler MP. Identification of JAK/STATpathway regulators-insights from RNAi screens. Identifica-tion of JAK/STAT pathway regulators-insights from RNAiscreens[J]. Ann Biol Clin (Paris) ,2012,70(5):591-594.
-
10路秀英,李晓明,王俊阁.JAK2激酶抑制剂AG490抑制喉鳞癌细胞侵袭力的实验[J].肿瘤防治研究,2008,35(9):664-664. 被引量:2
同被引文献6
-
1WEI Ju,WANG Chun,QIN You-wen,ZHU Jun,GAO Yang-rong,CAI Qi,YAN Shi-ke.JAK2 V617F positive essential thrombocythemia developing in a patient with CD5-chronic lymphocytic leukemia[J].Chinese Medical Journal,2012(11):2076-2079. 被引量:1
-
2张颖,李佳宁,杜天颀,祁冰玉,孙平.对比不同静脉放血方法治疗真性红细胞增多症的临床效果[J].现代生物医学进展,2014,14(8):1562-1564. 被引量:6
-
3王容,张珊,马勋泰.伴肾小管酸中毒的真性红细胞增多症1例[J].第三军医大学学报,2014,36(8):846-846. 被引量:2
-
4卢媛,高明,魏佳,王静.红细胞单采在真性红细胞增多症治疗中的应用[J].临床血液学杂志(输血与检验),2014,27(2):327-328. 被引量:5
-
5黄刚,梅竹君,高幼奇,谢旭芳,张昆南,吴晓牧.以颅内静脉窦血栓形成首发的真性红细胞增多症10例临床分析[J].中风与神经疾病杂志,2015,32(3):248-250. 被引量:4
-
6丁莉,许娜,黄彬涛,高冠论,肖雅娟,周璇,卢绮思,李琳,李玉玲,黄继贤,刘晓力.干扰素治疗慢性骨髓增殖性肿瘤的临床意义[J].肿瘤防治研究,2015,42(4):385-388. 被引量:2
二级引证文献5
-
1刘洁,陈哲,张斌,佟长青.小剂量肠溶阿司匹林对真性红细胞增多症患者凝血功能的影响[J].川北医学院学报,2017,32(5):721-724. 被引量:3
-
2黄晓春,秦丽娟,梁晔,李小梅.干扰素α和羟基脲治疗JAK2V617F基因突变阳性骨髓增殖性肿瘤的临床分析[J].中外医疗,2020,39(3):93-96. 被引量:5
-
3谭怡,饶治嫦,阳梅,赖玲,王娟.放血疗法联合羟基脲或干扰素治疗真性红细胞增多症的疗效及对血清EPO和血象指标的影响[J].西部医学,2021,33(10):1468-1472. 被引量:7
-
4常明霞.α-干扰素联合羟基脲治疗原发性血小板增多症的效果[J].临床医学,2022,42(2):113-114. 被引量:7
-
5孔梦影,朱咪咪,于得泓,朱历宏,李丽.真性红细胞增多症的诊疗进展[J].世界最新医学信息文摘,2017,17(86):81-82. 被引量:5
-
1任华,周春华.超声刀在经肛直肠肿瘤局部切除术中的应用[J].中华胃肠外科杂志,2010,13(8):603-603.
-
2王昊.少女怀疑自己乳腺癌 原来颅内长了垂体瘤[J].健康博览,2015,0(3):12-12.
-
3孟文.“吃货”吃不下 一查竟是食管癌[J].健康博览,2015,0(3):12-12.
-
4汪荣,韩志江,舒艳艳.16层螺旋CT在原发性腹膜后神经源性肿瘤诊断中的价值[J].浙江医学,2010(11):1712-1714.
-
5谷莹,雷志锴,韩志江,包凌云,武剑,丁金旺.多种超声征象联合对直径>1.0cm甲状腺乳头状癌的预测价值[J].中华医学超声杂志(电子版),2016,13(12):925-930. 被引量:3
-
6高国栋,王平,张方捷,叶静,黄永刚.腹腔镜治疗腹股沟疝合并精索或子宫圆韧带囊肿14例体会[J].中华疝和腹壁外科杂志(电子版),2016,10(4):296-297. 被引量:3
-
7朱罗茜,包凌云,朱庆庆,谭艳娟.自动乳腺全容积成像技术及常规超声检查鉴别诊断乳腺影像报告和数据系统4类病灶良恶性的价值比较[J].中华医学超声杂志(电子版),2016,13(12):931-935. 被引量:19
-
8封光华,贾忠,沈伟敏,单毓强.十二指肠乳头部良性肿瘤局部切除12例临床分析[J].中华普通外科杂志,2011,26(2):158-159. 被引量:4
-
9包凌云,谭艳娟,朱罗茜,许晓静,孔凡雷,刘坚,朱庆庆.自动乳腺全容积成像在乳腺导管原位癌诊断中的应用价值[J].中华医学超声杂志(电子版),2015,12(1):53-56. 被引量:27
-
10王于勇,于志坚,何华东,王旭亮,葛宏伟,谢玺.输尿管内翻性乳头状瘤癌变伴同侧肾细胞癌、膀胱移行细胞癌1例报告[J].肿瘤学杂志,2016,22(8):691-692.